Combination of oncolytic virotherapy with small molecules targeting the MEK-ERK pathway has also been shown to induce more profound antitumor efficacy than monotherapy in in vivo tumor models with KRAS/BRAF mutations [36]. This evidence concerns the gene KRAS and neoplasm.